<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02438852</url>
  </required_header>
  <id_info>
    <org_study_id>4B-14-4</org_study_id>
    <secondary_id>NCI-2015-00279</secondary_id>
    <secondary_id>4B-14-4</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT02438852</nct_id>
  </id_info>
  <brief_title>Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer</brief_title>
  <official_title>Efficacy of Continuous Infusion of Local Anesthesia After Radical Cystectomy: A Randomized, Double Blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase IV trial studies how well the continuous infusion of ropivacaine
      hydrochloride works in reducing pain after surgery in patients with bladder cancer.
      Ropivacaine hydrochloride is an anesthetic drug used to decrease pain by numbing an area of
      the body without putting the patient to sleep. Continuous infusion of ropivacaine
      hydrochloride may reduce pain and improve the quality of life for patients after bladder
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine if continuous infusion of local anesthesia (CILA) decreases post-operative
      pain after radical cystectomy (RC).

      II. To determine if CILA reduces narcotic requirements after RC.

      SECONDARY OBJECTIVES:

      I. To determine if CILA decreases length-of-stay after RC. II. To determine if CILA improves
      patients satisfaction with post-operative pain control after RC.

      OUTLINE: Patients are randomized to 1 of 2 arms.

      ARM I: Patients receive ropivacaine hydrochloride intravenously (IV) continuously over 72
      hours after radical cystectomy.

      ARM II: Patients receive normal saline (placebo) IV continuously over 72 hours after radical
      cystectomy.

      After completion of study, patients are followed up within 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Narcotic requirement</measure>
    <time_frame>Up to 72 hours after surgery</time_frame>
    <description>Total narcotic dose after surgery until 72 hours will be analyzed as continuous variables and will be compared with the one sided t-test in an intention-to-treat manner.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>The length of hospitalization will be analyzed as continuous variables and will be compared with the one sided t-test in an intention-to-treat manner.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Bladder Carcinoma</condition>
  <condition>Post-operative Pain</condition>
  <arm_group>
    <arm_group_label>Arm I (ropivacaine hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ropivacaine hydrochloride IV continuously over 72 hours after radical cystectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive normal saline (placebo) IV continuously over 72 hours after radical cystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (ropivacaine hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (ropivacaine hydrochloride)</arm_group_label>
    <other_name>Naropin</other_name>
    <other_name>Ropivacaine Hydrochloride Monohydrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing elective open radical cystectomy

          -  Ability to understand and the willingness to sign a written informed consent

        Exclusion Criteria:

          -  Allergy or adverse reaction to ropivacaine (ropivacaine hydrochloride) or any amide
             type of local anesthesia

          -  Allergy or adverse reaction to local anesthesia catheter

          -  Additional surgery at the same time as RC (e.g. nephroureterectomy)

          -  Coagulopathy

          -  Thrombocytopenia

          -  Local or systemic infection

          -  Pregnancy

          -  Chronic hepatic disease

          -  Use of type III antiarrhythmics (e.g. amiodarone)

          -  History of chronic pain and/or daily opioid use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siamak Daneshmand</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ileana Aldana</last_name>
    <phone>323-865-0702</phone>
    <email>Ileana.aldana@med.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ileana Aldana</last_name>
      <phone>323-865-3700</phone>
      <email>Ileana.aldana@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Siamak Daneshmand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

